Remote Acute Assessment Of Patients With High Cardiovascular Risk Post-Acute Coronary Syndrome (TELE-ACS)

Key Points:

TELE-ACS evaluates the use of telemedicine strategies to reduce hospital readmission rates in patients with a recent history of acute coronary syndrome
There was a 76% reduction in hospital readmission in the first six months for patients with a history of ACS who received the telemedicine intervention compared to controls (HR: 0.24, 95% CI: 0.13-0.44, p < 0.00)
The use of a telemedicine intervention resulted in a 41% reduction in emergency department visits (HR: 0.59, 95% CI HR: 0.40-0.89, p < 0.001)

An “Inclisiran First” Strategy Shows Greater LDL-C Lowering Compared With Usual Care In Patients With ASCVD: The VICTORION-INITIATE Randomized Trial

Key Points:

Most patients with atherosclerotic cardiovascular disease (ASCVD) do not achieve sufficiently reduced low-density lipoprotein cholesterol (LDL-C) levels despite maximum-tolerated lipid-lowering therapy (LLT) to improve cardiovascular outcomes.
Twice-yearly inclisiran therapy added to maximum-tolerated statin therapy reduces LDL levels by an additional 50% compared to maximum-tolerated statin therapy alone.
The investigators randomized 450 participants to either inclisiran 284 mg at day 0, day 90, and day 270 plus usual LLT versus usual LLT alone.

The “inclisiran-first” strategy resulted in greater reductions in LDL and more patients reaching goal LDL reduction with minimal and comparable adverse effects.

Key Points:

Incident heart failure remains common among patients who experience acute myocardial infarction despite recent advances in medical therapy and revascularization strategies.
The EMPACT MI trial randomized 6,522 participants with acute myocardial infarction (STEMI or NSTEMI) at high risk of heart failure to empagliflozin 10mg daily or placebo.
Over a median follow-up of 17.9 months, the primary endpoint of time to first heart failure hospitalization or all-cause mortality was not significantly reduced with empagliflozin.